thermogelling polymer drug delivery

Absco Therapeutics develops targeted local immunotherapies for solid tumors, starting with cervical precancer, to avoid surgery and prevent recurrence. Its platform uses thermogelling polymers that transform from liquid to solid at body temperature, holding position on injection to create controlled-release drug depots for immune education. Its lead candidate ABS005 is a non-surgical treatment for high-grade Cervical Intraepithelial Neoplasia (CIN2/3).

Read more

controlled-release drug depotsincorporation of small molecules, proteins, and nucleic acidssustained intralesional delivery